Tanis: I think we'll get the LP-2 (bridge) data in the next week or so. Then we'll get the 12 week validation data from ICON in December. But from the CC I did not get the impression we'd get a "classic partner' for Lympro until well after we've started commercialization and Big Pharma realizes how valuable it is. That is all very true, but many of us were under the impression he had already identified the partner several months ago and they were just putting together the final details.

Gerald probably should have made clearer that the partner he was speaking of was just a "master service agreement." Then we wouldn't have expected to get such a pop in September.